Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab and Sacituzumab Govitecan in Metastatic TNBC
NCT07011654Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2025
- Primary completion
- Jul 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of naxitamab in triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2025; status: recruiting.
02
Drugs
naxitamab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07011654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011654.